ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...
Wieme, R. J., Demeulenaere, L., and Segers, J., Prot. Biol. Fluids (Proc. Fifteenth Colloq., Bruges), 15, 499 (Elsevier, Amsterdam, 1968).
Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases – New Research Presented at 6 th ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results